<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> is the most common <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disorder</z:e> of the connective tissue with an estimated prevalence of 1:10,000 </plain></SENT>
<SENT sid="1" pm="."><plain>The disease is characterised by manifestations in the cardiovascular, skeletal and ocular systems </plain></SENT>
<SENT sid="2" pm="."><plain>The most severe manifestations are those of the cardiovascular system: <z:hpo ids='HP_0001634'>mitral valve prolapse</z:hpo> and dilation of the aortic root, which may progress to <z:hpo ids='HP_0002647'>aortic dissection</z:hpo>, a common cause of mortality in patients </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> is a dominant <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disorder</z:e> caused by mutations in the gene coding for fibrillin-1, the FBN1 gene </plain></SENT>
<SENT sid="4" pm="."><plain>Fibrillin, a 347 kDa <z:chebi fb="2" ids="17089">glycoprotein</z:chebi>, is found in most connective tissues and is a major component of the extracellular microfibrils </plain></SENT>
<SENT sid="5" pm="."><plain>More than 100 different FBN1 mutations have been identified in individuals with <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e>, the majority of which are unique missense point mutations </plain></SENT>
<SENT sid="6" pm="."><plain>Evidence suggests a dominant-negative mechanism of pathogenesis for the disorder, that is, the presence of the mutant fibrillin molecule interferes with the function of the <z:mpath ids='MPATH_458'>normal</z:mpath> protein </plain></SENT>
<SENT sid="7" pm="."><plain>Therapies for dominant disorders such as <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>) are likely to require both suppression of the disease allele expression and maintenance of expression of its <z:mp ids='MP_0002169'>wild-type</z:mp> counterpart </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, dominant <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disorders</z:e> present a unique therapeutic challenge </plain></SENT>
<SENT sid="9" pm="."><plain>One approach to developing a therapy would be to use catalytic nucleic acid molecules </plain></SENT>
<SENT sid="10" pm="."><plain>Antisense catalytic <z:chebi fb="40" ids="33697">RNAs</z:chebi>, or ribozymes, have been widely used to down-regulate or repair targeted gene expression respectively through the cleavage or trans-splicing of <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>Similarly, antisense DNA molecules or DNAzymes have been shown to be capable of cleaving target <z:chebi fb="40" ids="33697">RNA</z:chebi> molecules in a highly specific manner </plain></SENT>
<SENT sid="12" pm="."><plain>This review will discuss the potential of catalytic nucleic acid molecules as therapeutic agents for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> </plain></SENT>
</text></document>